Condition: HER2-positive Breast Cancer · HER2-low Breast Cancer · Breast Cancer · Sponsor: Daiichi Sankyo
This multi-center observational prospective study will collect real-world clinical and patient-reported outcome data from eligible patients with unresectable or metastatic HER2+ breast cancer who have received one or more prior anti-HER2-based regimens or patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+, ISH-) breast cancer who have received at least a prior systemic therapy in the metastatic setting, or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.
This description comes directly from the study's public registry record.
Daiichi Sankyo China · 0086-021-60397406 · yu.huan.m8@daiichisankyo.com.cn
Daiichi Sankyo Contact for Clinical Trial Information · 9089926400 · CTRinfo_us@daiichisankyo.com
Always discuss trial participation with your own doctor first.
| China-Japan Friendship Hospital | Beijing, China | Recruiting |
| Peking University First Hospital | Beijing, China | Recruiting |
| The Fifth Medical Center of the Chinese PLA General Hospital | Beijing, China | Withdrawn |
| Peking University Shougang Hospital | Beijing, China | Recruiting |
| Peking University Third Hospital | Beijing, China | Recruiting |
| Beijing GoBroad Hospital | Beijing, China | Recruiting |
| Sichuan Cancer Hospital | Chengdu, China | Recruiting |
| Sichuan Provincial People's Hospital | Chengdu, China | Recruiting |
| Affiliated Zhongshan Hospital of Dalian University | Dalian, China | Recruiting |
| The First People's Hospital of Foshan | Foshan, China | Recruiting |
| Fujian Cancer Hospital | Fuzhou, China | Recruiting |
| Affiliated Cancer Hospital and Institute of Guangzhou Medical University | Guangzhou, China | Withdrawn |
+ 42 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06210776